All In Biotech

Drug Trial Radar · NCT01861912

Arsenic Trioxide TACE and Intravenous Administration in Unresectable Hepatocellular Carcinoma

Arsenic Trioxide TACE and Intravenous Administration Compared With Arsenic Trioxide TACE Alone in Unresectable Hepatocellular Carcinoma: a Randomized, Parallel, Controlled, Multi-center Clinical Study

Last checked: Nov 20, 2026Latest source record: Jun 5, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 258 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

258

Planned (sponsor's estimate)

Start

Jun 2013

Primary completion

Jun 2016

Study completion Dec 2016

Sponsor

Lead sponsor
Guangdong Provincial People's HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 24, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether compared with arsenic trioxide TACE alone, arsenic trioxide TACE and intravenous administration could further prolong the overall survival.

Conditions

  • Carcinoma, Hepatocellular

Interventions

  • Arsenic trioxide TACEDevice

    Arsenic trioxide powder 20mg dissolved in lipiodol(the dosage of lipiodol is decided according to the volume of the target lesion)is used for transcatheter arterial chemoembolization(TACE). TACE will be repeated after 4\~6 weeks if it is necessary according to the assessment from imaging modalities

  • Arsenic trioxide intravenous infusionDrug

    Arsenic trioxide intravenous infusion: arsenic trioxide powder 0.15mg/Kg/d(maxim 10mg/d) dissolved in 250ml 0.9%NaCl solution is used for intravenous infusion.Every course will last for 3 weeks and the next course will be continued after 1 week suspension.Intravenous infusion will be suspended 3 days before and 7\~14 days after TACE.

  • lipiodolDrug

    Lipiodol is used to dissolve arsenic trioxide for TACE,with the dosage decided according to the volume of the target lesion.

  • NaCl solutionDrug

    250ml NaCl solution is used to dissolve the arsenic trioxide for intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to ProgressionTime frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.